Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 10:12:653-658.
doi: 10.2147/CIA.S128618. eCollection 2017.

Evaluation of EX-PRESS glaucoma implant in elderly diabetic patients after 23G vitrectomy

Affiliations

Evaluation of EX-PRESS glaucoma implant in elderly diabetic patients after 23G vitrectomy

Anita Lyssek-Boroń et al. Clin Interv Aging. .

Abstract

Purpose: The most frequent qualifications for pars plana vitrectomy (PPV) in diabetic patients include recurrent hemorrhage into the vitreous body chamber and vitreoretinal proliferation, also with traction retinal detachment. The aim of this study was to evaluate the effectiveness of EX-PRESS implant for the treatment of secondary glaucoma in elderly diabetic patients following PPV 23G with silicon oil or SF6 gas endotamponade.

Materials and methods: This retrospective analysis comprised 18 patients (19 eyes). We applied EX-PRESS implants in 9 patients with neovascular glaucoma (NVG) and in 10 patients with non-NVG. All patients had earlier history of diabetes and vitrectomy 23G for diabetic complications. Intraocular pressure (IOP) was measured and compared before; 7 days; 1, 3, 6, and 12 months; and a year after the surgery.

Results: Application of the implant exhibited a lowering effect on IOP. After 1 month, 53% of patients had IOP values beyond 22 mmHg, while 86% after 1 year.

Conclusion: The implant can be used to treat both NVG and non-NVG in diabetic patients following PPV.

Keywords: DM; IOP; PPV; glaucoma surgery.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
IOP before and after surgery. Abbreviation: IOP, intraocular pressure.
Figure 2
Figure 2
Comparison of intraocular pressure values in groups at subsequent observation times: patients with neovascular glaucoma and patients with secondary diabetic glaucoma, nonneovascular.
Figure 3
Figure 3
BCVA in all patients during the study. Abbreviation: BCVA, best-corrected visual acuity.
Figure 4
Figure 4
Survival analysis results (for all patients).
Figure 5
Figure 5
Survival analysis results for patients with neovascular and nonneovascular glaucoma.
Figure 6
Figure 6
Intraocular pressure in patients receiving no drugs. Abbreviation: IOP, intraocular pressure.

Similar articles

Cited by

References

    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–1053. - PubMed
    1. Al-Shabrawey M, Zhang W, McDonald D. Diabetic retinopathy: mechanism, diagnosis, prevention, and treatment. Biomed Res Int. 2015;2015:854593. - PMC - PubMed
    1. Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(suppl 1):S84–S87. - PubMed
    1. Gupta V, Arevalo JF. Surgical management of diabetic retinopathy. Middle East Afr J Ophthalmol. 2013;20(4):283–292. - PMC - PubMed
    1. Samuelson TW, Stamper R, Gallardo M. Flow dynamics of the EX-PRESS® glaucoma filtration device. US Ophthalmic Rev. 2014;7(1):39.